Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

10 results about "Conjugated protein" patented technology

A conjugated protein is a protein that functions in interaction with other (non-polypeptide) chemical groups attached by covalent bonding or weak interactions. Many proteins contain only amino acids and no other chemical groups, and they are called simple proteins. However, other kind of proteins yield, on hydrolysis, some other chemical component in addition to amino acids and they are called conjugated proteins. The non-amino part of a conjugated protein is usually called its prosthetic group. Most prosthetic groups are formed from vitamins. Conjugated proteins are classified on the basis of the chemical nature of their prosthetic groups.

Recombinant conjugated protein against ebv virus and application thereof

This invention provides a recombinant conjugate protein against EBV virus and its application. The recombinant conjugate protein is a conjugate of recombinant protein HBc-SC and recombinant EBV antigen protein. In the recombinant conjugate protein, the molar ratio of recombinant protein HBc-SC to recombinant EBV antigen protein is 1:1 to 1:12. The amino acid sequence of the recombinant protein HBc-SC is shown in SEQ ID NO:1. The recombinant EBV antigen protein includes a recombinant gHgL fragment and a tag sequence. The recombinant gHgL fragment is shown in SEQ ID NO:3. The tag sequence is shown in SEQ ID NO:5, and the tag sequence is located at the C-terminus of the recombinant EBV antigen protein. The recombinant conjugate protein provided by this invention can induce strong humoral immunity, significantly increasing neutralizing antibody titers in epithelial cells and B cells, making it an excellent candidate vaccine for preventing EBV virus infection.
Owner:SHANGHAI INSTITUTE OF INFECTIOUS DISEASE & BIOSECURITY

Prussian blue nano test strip for detecting African horse pestivirus antibody as well as preparation method and application of Prussian blue nano test strip

PendingCN121978329AMaterial analysisViral antibodyStaphylococcus
The invention belongs to the technical field of biology, and particularly relates to a Prussian blue nano test strip for detecting an African horse pestivirus antibody as well as a preparation method and application of the Prussian blue nano test strip. A sample pad, a combination pad, a chromatography detection membrane and a water absorption pad are sequentially fixed on the supporting bottom plate; the chromatography detection membrane is provided with a detection line and a quality control line, the detection line is coated with staphylococcus A protein, and the quality control line is coated with a monoclonal antibody of African horse pestivirus VP7 recombinant protein; and the combination pad is coated with an African horse pestivirus VP7 delta N1-129 recombinant protein fragment coupled with Prussian blue nanoparticles. According to the invention, Prussian blue nano is used as a coupling tracer, and the specific reaction of an antigen and an antibody is fully utilized to detect the African horse pestivirus antibody. After the conjugate is combined with a corresponding antibody, a result can be clearly observed, and the conjugate is good in stability, high in sensitivity and strong in specificity, has a clinical application function and huge development potential, and is an extremely ideal antibody test strip detection material.
Owner:ANIMAL AND PLANT & FOOD DETECTION CENTER JIANGSU ENTRY EXIT INSPECTION AND QUARANTINE BUREAU +1

Extracellular matrix binding compounds for localized loading of therapeutic or diagnostic agents - Patent Application 20070122999

PendingJP2026500221AOrganic active ingredientsPeptide/protein ingredientsDiseaseExtracellular matrix binding
A major obstacle in the field of biotherapeutics is the need for platform technologies that enable high bioavailability and long-term therapeutic exposure of biotherapies in localized disease. Traditional approaches result in problematic trade-offs, such as toxicity and off-target side effects. The present disclosure provides compounds comprising follistatin domain 1 (FSD1) of follistatin (FST), which can bind to biological structures, such as the extracellular matrix, via heparan sulfate without the undesired neutralizing effects on the activity of activin A, myostatin, and GDF11, as full-length follistatin does. The present invention relates to fusion or conjugated proteins, compositions thereof, constructs or vectors encoding them, their medical uses, and methods for biotherapeutics.
Owner:KAMINO APS

Bifunctional compounds for targeting PKMYT1 and methods of use

PendingJP2026529125ADiseaseThreonine
This invention discloses a bifunctional compound containing a targeting moiety for a conjugated protein kinase, membrane-bound tyrosine / threonine 1 (PKMYT1), a pharmaceutical composition thereof, and a method for treating PKMYT1-related disorders or diseases, such as cancer.
Owner:INSILICO MEDICINE IP LTD

Bucket (Baojian Compound Protein Powder Solid Beverage)

ActiveCN309830662SConjugated proteinEngineering
1. Name of the product for this design: Bucket (Baojian Compound Protein Powder Solid Beverage). 2. Purpose of this design: For packaging health food products. 3. The key design features of this product are the combination of shape and pattern. 4. The image or photograph that best illustrates the design's key features: the front view.
Owner:BAOJIAN (BEIJING) BIOTECHNOLOGY CO LTD

Methods and compositions related to evolving botulinum toxin proteases for targeted substrate specificities

PCT designated stageWO2026178072A1Protein targetConjugated protein
This invention provides libraries of Botulinum neurotoxin A (BoNT / A) protease variants for stepwise evolution of the enzyme to generate BoNT / A variants that can specifically cleave a desired cleavage site in a target protein. Related methods for performing stepwise evolution of BoNT / A with the BoNT / A variant libraries and simultaneous stepwise evolution of a desired substrate sequence in a target protein are also provided by the disclosure. Additionally provided in the disclosure are specifically evolved BoNT / A variant enzymes and conjugate proteins that specifically degrade intrinsically disordered proteins (IDPs) that are involved in human deceases, e.g., a-Synuclein. Polynucleotide sequences encoding the engineered BoNT / A proteases, expression vectors and related pharmaceutical compositions are also provided in this disclosure. Further encompassed by the invention are therapeutic methods that utilize the engineered BoNT / A enzymes in the treatment of various synucleinopathies.
Owner:THE SCRIPPS RES INST

High-throughput parallel synthesis of small molecule degraders

Disclosed herein are high-throughput synthetic methods for deliberately and prospectively discovering molecular glues that can be used to form complex protein-ligand surfaces that facilitate interfacial binding to other proteins on a dispersed surface. Specifically, the present application discloses a high-throughput method that uses sulfur(VI) fluoride exchange (SuFEx) transformation and N-hydroxysuccinimide (NHS)-ester derivatized amide coupling to prospectively repurpose known ligands of a protein of interest as degraders and compounds capable of inducing proximity to other proteins. Disclosed herein are methods of developing known ligands of a target protein into degraders of the target protein. Also disclosed are methods of developing a novel small molecule chromatin-competitive inhibitor of the 11-19 Leukemia (ENL) YEATS domain into an effective degrader of ENL.
Owner:THE SCRIPPS RES INST

Systems and methods for analyzing antibody co-formulations

The present disclosure provides a system and method for detecting and quantifying two or more different antigen-binding proteins in a sample, which includes donor beads, acceptor beads, and conjugated proteins that can be incubated with the sample and the antigen-binding proteins quantified by a proximity-based homogeneous assay.
Owner:AMGEN INC

Packaging box (Baojian compound protein powder solid beverage)

ActiveCN309836996SBiotechnologyConjugated protein
1. Name of the designed product: package box (Baojian compound protein powder solid beverage). 2. Use of the designed product: for packaging health food. 3. Design points of the designed product: combination of shape and pattern. 4. Picture or photo best indicating the design points: front view.
Owner:BAOJIAN (BEIJING) BIOTECHNOLOGY CO LTD

Preparation and weeding application of composite protein-based nano quinclorac material

The invention discloses preparation and weeding application of a composite protein-based nano quinclorac material, and belongs to the technical field of pesticide weeding. The method comprises the following steps: forming a compound protein solution by adopting isolated soybean protein and isolated whey protein in a specific proportion, adding quinclorac into the compound protein solution, fully mixing, and regulating the pH value of the system to 6.0-8.0; centrifuging, collecting supernate, and performing freeze drying to obtain the target composite protein-based nano quinclorac material. Experimental results show that the material shows excellent drug loading capacity, and the bioavailability of quinclorac is remarkably improved. In the weeding application, the material not only can efficiently remove weeds and reduce the herbicide application amount, but also enhances the safety to non-target organisms; meanwhile, the fertilizer has the functions of promoting the activity of effective microbial communities in soil and relieving pesticide stress, so that the soil health is effectively protected.
Owner:JIANGNAN UNIV